Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGGT1B | P53609 | 6/20 | 0.55 |
| ▸ | FNTA | P49354 | 8/20 | 0.52 |
| ▸ | FNTB | P49356 | 8/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6990125 | 0.88 | FNTA (0.60) | PGGT1BFNTAFNTB | |
| SCHEMBL7091209 | 0.85 | PGGT1B (0.60) | PGGT1BFNTAFNTB | |
| SCHEMBL7091126 | 0.84 | FNTA (0.63) | PGGT1BFNTAFNTB | |
| SCHEMBL7570376 | 0.80 | FNTA (0.49) | PGGT1BFNTAFNTB | |
| SCHEMBL7577172 | 0.77 | PGGT1B (0.55) | PGGT1BFNTAFNTB | |
| SCHEMBL7569335 | 0.77 | FNTA (0.61) | PGGT1BFNTAFNTB | |
| SCHEMBL7092689 | 0.76 | FNTA (0.56) | PGGT1BFNTAFNTB | |
| SCHEMBL7092079 | 0.74 | FNTA (0.54) | PGGT1BFNTAFNTB | |
| SCHEMBL7092400 | 0.72 | FNTA (0.69) | PGGT1BFNTAFNTB | |
| SCHEMBL7090668 | 0.71 | PGGT1B (1.00) | PGGT1BFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1276726-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | disclosed |
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
| WO-2001081316-A2 | SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | PGGT1B 16/4885FNTA 1/4885FNTB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.